[HTML][HTML] Phosphatidylinositol 3-kinase α–selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.gov
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered
Solid Tumors: Results From the First-in-Human Study - PMC Back to Top Skip to main content
NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal
List J Clin Oncol PMC5920739 Other Formats PDF (878K) Actions Cite Collections Share
Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases …
Solid Tumors: Results From the First-in-Human Study - PMC Back to Top Skip to main content
NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal
List J Clin Oncol PMC5920739 Other Formats PDF (878K) Actions Cite Collections Share
Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases …
Abstract
Purpose
We report the first-in-human phase Ia study to our knowledge (ClinicalTrials. gov identifier:
ncbi.nlm.nih.gov